# The role of gut microbes and microbial derived metabolites in the development of type 2 diabetes in humans

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $642,673

## Abstract

PROJECT SUMMARY
Mounting evidence links the gut microbiome – the modifiable “second genome” consisting of trillions
of diverse microbes that inhabit the human gut – with type 2 diabetes mellitus (T2DM) in humans.
Studies using fecal transplant in mice have raised the central hypothesis that changes of the gut
microbiome and the biochemical by-products originated from these microbes may be key modulators
of development of T2DM. To date, however, knowledge of the specific microbial species that drive the
development of T2DM in humans remain very limited. Human studies of the gut microbiome in T2DM
have largely been cross-sectional and confounded by reverse causality. Indeed, many of the gut
microbiome changes observed in human T2DM have been found to be a consequence of the disease
or treatments, including the medication metformin, rather than a cause of T2DM. In addition, the
circulating metabolites derived from the gut microbes that contribute to the development of T2DM
remain to be discovered. In this Early Stage Investigator NIH R01 application, we propose the largest
prospective study of the role of gut microbiome in T2DM using a Finnish cohort of 6921 individuals
with fecal and plasma samples collected in 2002 and over 15 years of subsequent clinical follow up.
This proposed study brings together a diverse team with deep expertise in the human microbiome,
mass-spectrometry based metabolomics, computational biology, statistical epidemiology, and
diabetes pathobiology, to specifically address the key biological and clinical questions regarding the
role of gut microbes and microbial derived metabolites in the development of incident T2DM in
humans.

## Key facts

- **NIH application ID:** 10657617
- **Project number:** 5R01DK129840-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Amit Majithia
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $642,673
- **Award type:** 5
- **Project period:** 2021-08-02 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10657617

## Citation

> US National Institutes of Health, RePORTER application 10657617, The role of gut microbes and microbial derived metabolites in the development of type 2 diabetes in humans (5R01DK129840-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10657617. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*